- Home
- SOL vs MGNX Comparison
SOL vs MGNX Comparison
Compare SOL & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- MGNX
- Stock Information
- Founded
- SOL 2005
- MGNX 2000
- Country
- SOL United States
- MGNX United States
- Employees
- SOL N/A
- MGNX N/A
- Industry
- SOL Semiconductors
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- MGNX Health Care
- Exchange
- SOL Nasdaq
- MGNX Nasdaq
- Market Cap
- SOL 98.5M
- MGNX 99.7M
- IPO Year
- SOL 2008
- MGNX 2013
- Fundamental
- Price
- SOL $1.88
- MGNX $1.59
- Analyst Decision
- SOL Strong Buy
- MGNX Hold
- Analyst Count
- SOL 2
- MGNX 5
- Target Price
- SOL $4.50
- MGNX $3.25
- AVG Volume (30 Days)
- SOL 118.1K
- MGNX 960.4K
- Earning Date
- SOL 11-13-2025
- MGNX 11-04-2025
- Dividend Yield
- SOL N/A
- MGNX N/A
- EPS Growth
- SOL N/A
- MGNX N/A
- EPS
- SOL N/A
- MGNX N/A
- Revenue
- SOL $68,445,000.00
- MGNX $165,495,000.00
- Revenue This Year
- SOL N/A
- MGNX N/A
- Revenue Next Year
- SOL $45.37
- MGNX N/A
- P/E Ratio
- SOL N/A
- MGNX N/A
- Revenue Growth
- SOL N/A
- MGNX 303.47
- 52 Week Low
- SOL $1.04
- MGNX $0.99
- 52 Week High
- SOL $3.00
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- SOL 53.12
- MGNX 45.01
- Support Level
- SOL $1.81
- MGNX $1.68
- Resistance Level
- SOL $1.88
- MGNX $1.77
- Average True Range (ATR)
- SOL 0.03
- MGNX 0.16
- MACD
- SOL 0.00
- MGNX -0.02
- Stochastic Oscillator
- SOL 81.33
- MGNX 3.08
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.